April 2013 Vol 6 No 3 Payers’ Guide to New FDA Approvals

Select Drug Profiles, Payers' Guide

Zaltrap: A New Option for the Treatment of Patients with Metastatic Colorectal Cancer Resistant to or Progressing After an Oxaliplatin-Containing Regimen

Lynne Lederman, PhD, Medical Writer

Select Drug Profiles, Payers' Guide

Zytiga Receives an Expanded Indication for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy

Select Drug Profiles, Payers' Guide

Zioptan Receives FDA Approval for Patients with Open-Angle Glaucoma and/or Ocular Hypertension

Select Drug Profiles, Payers' Guide

Linzess: A Novel Treatment Option for Constipation Associated with Irritable Bowel Syndrome

Alice Goodman, Medical Writer

Select Drug Profiles, Payers' Guide

Perjeta: A New Option for Patients with HER2-Positive Metastatic Breast Cancer

Alice Goodman, Medical Writer

FDA Approvals, Drug Updates, Payers' Guide

Trends in the 2013 Pharmaceutical Pipeline

Dalia Buffery, MA, ABD, Atheer A. Kaddis, PharmD

Select Drug Profiles, Payers' Guide

Iclusig: A New Treatment Option for Adults with CML or Ph+ ALL that Is Resistant/ Intolerant to Previous Therapy with TKIs

Lynne Lederman, PhD, Medical Writer

Select Drug Profiles, Payers' Guide

Qsymia: Combination Oral Therapy a New Weight-Loss Option for Obese or Overweight Patients

Select Drug Profiles, Payers' Guide

Rayos: A Novel Oral Delayed-Release Prednisone for the Treatment of Rheumatoid Arthritis and Other Inflammatory Diseases

Alice Goodman, Medical Writer

Select Drug Profiles, Payers' Guide

Xeljanz: A New Treatment Option for Patients with Rheumatoid Arthritis

Alice Goodman, Medical Writer

1
2

Page 1 of 2
Results 1 - 10 of 20

Copyright © Engage Healthcare Communications, LLC. All rights reserved.